Cargando…

Universal COVID-19 vaccination cost saving unless anaphylaxis rate high

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997491/ http://dx.doi.org/10.1007/s40278-021-93011-2

Ejemplares similares

Expediting COVID-19 vaccination increases QALYs and saves costs in the USA
Publicado: (2021)

Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis
Publicado: (2021)

COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
Publicado: (2021)

Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan
Publicado: (2021)

Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Remote pulse-ox monitoring for COVID-19 patients saves costs, improves outcomes in the USA
Publicado: (2021)

Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021)

COVID-19 vaccination predicted to be cost effective in USA
Publicado: (2021)

Implementation of the “No ICU – Unless” approach in postoperative neurosurgical management in times of COVID-19
por: Qasem, Lina-Elisabeth, et al.
Publicado: (2022)

Implementation of the “No ICU – Unless” approach in postoperative neurosurgical management in times of Covid-19
por: Qasem, L.-E., et al.
Publicado: (2022)

Productivity losses impact cost effectiveness of COVID-19 vaccine
Publicado: (2021)

Anaphylaxis after COVID-19 vaccination: A registry-based study
por: Jaggers, Jordon, et al.
Publicado: (2022)

Correction to: Implementation of the “No ICU – Unless” approach in postoperative neurosurgical management in times of COVID‑19
por: Qasem, Lina‑Elisabeth, et al.
Publicado: (2023)

AstraZeneca COVID-19 vaccine: no increased rate of VTE
Publicado: (2021)

Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines
por: Maltezou, Helena C., et al.
Publicado: (2022)

Schematic memories develop quickly, but are not expressed unless necessary
por: Tompary, Alexa, et al.
Publicado: (2020)

Humancentric: technology fails unless it means something to someone
por: Saunders, Mike
Publicado: (2020)

Methylprednisolone life-saving in SARS?
Publicado: (2013)

Estimated direct costs of COVID-19 pandemic high in Turkey, but true costs "undoubtedly higher"
Publicado: (2021)

Expected rates of adverse events after COVID-19 vaccination in USA
Publicado: (2022)

Covid19: Unless one gets everyone to act, policies may be ineffective or even backfire
por: Muscillo, Alessio, et al.
Publicado: (2020)

Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines
Publicado: (2022)

COVID-19 vaccin et anaphylaxie()
por: Joob, B., et al.
Publicado: (2021)

Never Repeat the Same Trick Twice—Unless it is Cognitively Impenetrable
por: Ekroll, Vebjørn, et al.
Publicado: (2018)

Reported rates of CVST due to COVID-19 vaccination rose after publicising these ADRs
Publicado: (2022)

A Cage Is a Cage, Unless You Educate. Rhetoric Negatively Impacts Support for a Novel Housing System for Laying Hens Unless the Public Are Educated
por: Nolan, Huw R. J., et al.
Publicado: (2022)

Anaphylaxis after Moderna COVID-19 vaccine
por: Mayfield, Jeremy, et al.
Publicado: (2021)

NOT THE VACCINE, BUT ANAPHYLAXIS TO THE COVID-19 VIRUS ITSELF
por: PAROYA, AZZAM, et al.
Publicado: (2022)

Ocular antigen does not cause disease unless presented in the context of inflammation
por: Voigt, Valentina, et al.
Publicado: (2017)

Facial impression of trustworthiness biases statement credibility unless suppressed by facemask
por: Marini, Marco, et al.
Publicado: (2022)

Costs of active COVID-19 testing in Canada
Publicado: (2020)

Cost-benefit of COVID-19 lockdown in the UK
Publicado: (2020)

Acute Severe Anaphylaxis in Nepali Patients with Neurotoxic Snakebite Envenoming Treated with the VINS Polyvalent Antivenom
por: Sharma, Sanjib Kumar, et al.
Publicado: (2019)

A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies
por: Shaker, Marcus, et al.
Publicado: (2021)

Counting the cost of COVID-19 at the peak of the pandemic in Spain
Publicado: (2021)

Testing and restrictions are cost-effective COVID-19 measures
Publicado: (2021)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
por: Turner, Paul J., et al.
Publicado: (2021)

Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n43lat9imk6ci5a5dojk8fjmpr